Telithromycin, which is the representative of ketolides, has come into market in 2001. It shows very good activity against some macrolide-resistant bacteria.
The invention concerns a novel therapeutic application of ketolides for preparing pharmaceutical compositions for preventing arterial thrombotic complications related to atherosclerosis.